SynthesisInternational journal of clinical oncology2026
BRAF-targeted therapy in non-melanomatous BRAF-mutant tumours: a systematic review of broad but histology-modulated efficacy.
Synthesis in International journal of clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTumour agnostic therapies represent a paradigm shift in oncology. BRAF inhibitors have demonstrated efficacy in melanoma. However, their role in non-melanomatous cancers was originally contentious. This systematic review aims to evaluate the safety and efficacy of BRAF-targeted therapies, both as monotherapy and in combination with other targeted therapies, in BRAF-mutated, non-melanomatous tumours.
methodsA systematic search of MEDLINE, PubMed, EMBASE and Cochrane CENTRAL was conducted from January 2010 to January 2025. Eligible studies included prospective and retrospective trials as well as cohort studies assessing BRAF inhibitors in non-melanomatous cancers. Primary outcomes included objective response rate, progression free survival, duration of response and overall survival.
resultsThirty-six studies comprising 3141 patients were included, spanning over 14 tumour types. The majority (78%) were phase II basket trials. Colorectal (n = 1569, 50%), lung (n = 756, 24%) and thyroid (n = 114, 4%) were the most commonly represented tumour types. Combination therapy (e.g., BRAF and MEK inhibition concurrently) demonstrated superior efficacy to monotherapy (e.g. ORR 45-51% v 5-20% in colorectal cancer), with efficacy varying by histology. Toxicity profiles were consistent with known class effects and higher with more frequent ≥ grade 3 adverse events in combination therapy compared with monotherapy. Most studies included exhibited a moderate risk of bias due to single-arm design and lack of randomisation.
conclusionAlthough BRAF-targeted therapies have been positioned within the tumour-agnostic paradigm, the available evidence suggests clinically meaningful activity across multiple non-melanomatous BRAF-mutant tumours that is nevertheless modified by tumour lineage, biological context, and treatment strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.